NVDA+2.54%AAPL+1.32%GOOGL−1.62%MSFT+0.20%AMZN−0.10%TSM+1.60%SPCX+7.79%META+0.47%
StockVS

NASDAQ · Biotechnology · USD

AbCellera Biologics Inc. (ABCL) Stock Analysis

AbCellera Biologics Inc. (ABCL) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

Last Updated: October 21, 2026

ABCL

$12.24

+$0.53 (+4.53%)

Oct 21, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare ABCL with… →

ABCL Key Statistics

As of Oct 21, 2026
Trading
Open
$11.78
Previous Close
$11.71
Day's Range
11.59–12.37
52-Week Range
2.75–15.02
Volume
3.20M
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
1.41
Valuation
Market Cap
$3.97B
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
59.94
EPS (ttm)Profit attributable to each share over the last twelve months.
−0.54
Financials (FY)
Revenue (FY)
$75.13M+160.56%
Net Income (FY)
−$146.41M
Profit marginThe share of revenue left as profit after all costs and taxes.
−248.84%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
324.05M
1-Year Return
+119.35%
Dividend and dates
Earnings Date
November 9, 2026
Avg Volume
6.57M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

Key facts

As of October 21, 2026, ABCL closed at $12.24, +119.35% over 1 year.

AbCellera Biologics Inc. (ABCL) has a market capitalization of $3.97B.

In fiscal 2025, ABCL reported revenue of $75.13M.

ABCL Stock Return by Calendar Year

AbCellera Biologics Inc. (ABCL) return since Dec 2020: what $10,000 became

1 year
$10,000 $21,935
+119.35%
5 years
$10,000 $7,509
−24.91%
Since Dec 2020
$10,000 $2,078
−79.22%

If you had invested $10,000 in AbCellera Biologics Inc. (ABCL) at the close on December 11, 2020, the earliest close on record here, it would have been worth $2,078 at the close on October 21, 2026: −79.22% in total, −23.52% a year, over a partial period shorter than 10 years. A historical calculation from closing prices adjusted for splits and dividends, before fees and taxes.

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)+257.89%
2025+16.72%
2024−48.69%
2023−43.63%
2022−29.16%
2021−64.46%
2020 (partial year)−31.68%

As of October 21, 2026.

ABCL Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$75.13M−$146.41M−194.9%
2024$28.83M−$162.86M−564.8%
2023$38.03M−$146.40M−385.0%
2022$485.42M$158.52M32.7%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$75.13M—−$203.21M−$146.41M−194.9%
2024$28.83M$28.83M−$301.15M−$162.86M−564.8%
2023$38.03M$38.03M−$223.05M−$146.40M−385.0%
2022$485.42M$418.99M$227.07M$158.52M32.7%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

ABCL Valuation vs Biotechnology Median

Median of 608 stocks
MetricABCLBiotechnology medianvs median
P/S ratio59.9413.304.5x the median
Profit margin−248.84%−38.31%210.5 pts below

Medians across 608 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of October 21, 2026.

Recent News

All 20 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

AbCellera Biologics Inc. (ABCL) is capitalised at $3.97B on the latest close. It is classified in the Biotechnology industry, within the Healthcare sector. The company reports 562 employees.

The 52-week range on file runs from $2.75 to $15.02. The most recent close on file for ABCL is $12.24, dated October 21, 2026. That is +$0.53 (+4.53%) against the previous close. The latest close sits 345.9% above that 52-week low.

Financial Health

In fiscal 2025, AbCellera Biologics Inc. reported revenue of $75.13M. Against the prior fiscal year total of $28.83M, that is a change of +160.56%. The same year closed with a net loss of $146.41M. The reported profit margin is −248.84%. That is 210.5 percentage points below the Biotechnology median of −38.31%. Trailing earnings per share are −0.54.

Across the 4 fiscal years on file, revenue moves from $485.42M in 2022 to $75.13M in 2025. Of those 4 years, 1 report positive net income.

Valuation Assessment

The record shows negative trailing earnings, so no price-to-earnings ratio is published. The price-to-sales ratio is 59.94. On price-to-sales that is 4.5 times the Biotechnology median of 13.3. The medians here are taken across 608 Biotechnology companies that report the metric.

The trailing one-year total return is +119.35%. Across 5 years the annualized return works out at −5.57%. Beta against the wider market is reported at 1.41. Daily returns over the trailing 5 years annualize to a volatility of 69.66%.

Growth & Income

No dividend is on file for ABCL.

So far in 2026 the total return is +257.89%. The strongest complete calendar year on file is 2025 at +16.72%; the weakest is 2021 at −64.46%. Of the 5 complete calendar years on file, 1 finished higher.

Peer Comparison

AbCellera Biologics Inc. (ABCL) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
AbCellera Biologics Inc. ABCL $3.97B —
Vertex Pharmaceuticals Incorporated VRTX $132.95B 30.4
Moderna, Inc. MRNA $98.14B —
Regeneron Pharmaceuticals, Inc. REGN $82.95B 19.9

The Biotechnology industry average P/E ratio is 16.6x. AbCellera Biologics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each daily rebuild. Informational only, not financial advice. As of October 21, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$132.95B

 MRNA

Moderna, Inc.

$98.14B

 REGN

Regeneron Pharmaceuticals, Inc.

$82.95B

 ARGX

argenx SE

$55.97B

 ONC

BeOne Medicines AG

$43.97B

 RVMD

Revolution Medicines, Inc.

$41.64B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.13T

 JNJ

Johnson & Johnson

$621.22B

 ABBV

AbbVie Inc.

$503.27B

 UNH

UnitedHealth Group Incorporated

$374.30B

 MRK

Merck & Co., Inc.

$369.78B
View all Healthcare stocks →

About AbCellera Biologics Inc.

AbCellera Biologics Inc. engages in discovering and developing antibody-based medicines for indications with unmet medical need in the United States. Its lead product is ABCL635, an non-hormonal medicine, which is in Phase 2 clinical trial to treat moderate-to-severe vasomotor symptoms; and ABCL575, a fully human, half-life extended monoclonal antibody, which is in in a Phase 1 clinical trial for treating T-cell-mediated autoimmune conditions, such as atopic dermatitis. The company has a research collaboration and license agreement with Eli Lilly and Company; AbbVie Inc.; Jazz Pharmaceuticals plc to develop T-cell engaging (TCE) multispecific antibodies; partnership agreement with Viking Global Investors & ArrowMark Partners and Biogen Inc.; and Vertex Pharmaceuticals Incorporated to research, develop, manufacture, and commercialize multispecific T-cell engagers (TCEs) for autoimmune diseases and other conditions. AbCellera Biologics Inc. was incorporated in 2012 and is headquartered in Vancouver, Canada.

Visit website →